AmphiArc3

General Information


DRACP ID  DRACP02764

Peptide Name   AmphiArc3

Sequence  AFRHSVKEELNYIRRRLERFPNRL

Sequence Length  24

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP Membrane-targeted



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
MCF-7 Invasive breast carcinoma of no special type Carcinoma EC50>50 µM MTT assay 24 h 1
A549 Lung adenocarcinoma Carcinoma EC50>50 µM MTT assay 24 h 1

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  DRACP02764

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C138H223N47O35

Absent amino acids  CDGMQTW

Common amino acids  R

Mass  351098

Pl  11.85

Basic residues  8

Acidic residues  3

Hydrophobic residues  8

Net charge  5

Boman Index  -10549

Hydrophobicity  -115.83

Aliphatic Index  81.25

Half Life 
  Mammalian: 1.3 hour
  Yeast: 3 min
  E.coli: 2 min

Extinction Coefficient cystines  1490

Absorbance 280nm  64.78

Polar residues  4

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 31375699

Title  In silico design and optimization of selective membranolytic anticancer peptides

Doi 10.1038/s41598-019-47568-9

Year  2019

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.